<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="bf755cb2-4316-4fa1-b4b9-330a64996c8b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 <br/>
      <br/>
      <br/>
      <br/>
NALFON (fenoprofen calcium, USP) capsules, for oral use
 <br/>
      <br/>
Initial U.S. Approval: 1982
</title>
   <effectiveTime value="20190807"/>
   <setId root="f9c6fd52-6e28-482c-8b76-bd111760a34c"/>
   <versionNumber value="5"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
            <name>Bryant Ranch Prepack</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                        <name>Bryant Ranch Prepack</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="REPACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63629-7515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="RELABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63629-7515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="325335f8-98b6-4505-a733-4db097d98a96"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20181025"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63629-7515" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Nalfon</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>fenoprofen calcium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="42195-308" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (15 MPA.S AT 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="400" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0X2CW1QABJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FENOPROFEN CALCIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RA33EAC7KY" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FENOPROFEN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63629-7515-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180124"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63629-7515-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180124"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="28" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63629-7515-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180124"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63629-7515-4" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180124"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="120" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63629-7515-5" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180124"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA017604" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20120827"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>opaque green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>opaque blue</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="23" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">NALFON400;EP123</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Box">
               <id root="742a418f-037e-4e8a-bd0c-1420ec6d33c5"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</title>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Non-Steroidal Anti-Inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. (
           
   
      <linkHtml href="#S5.1">5.1</linkHtml>)
          
  
     </content>
                           </item>
                        </list>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">NALFON is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (
           
   
      <linkHtml href="#S4">4</linkHtml>, 
           
   
      <linkHtml href="#S5.1">5.1</linkHtml>)
          
  
     </content>
                           </item>
                        </list>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (
           
   
      <linkHtml href="#S5.2">5.2</linkHtml>)
          
  
     </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="f6131fc6-93c4-4678-b2e9-3ec885584829"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Cardiovascular Thrombic Events</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Non-Steroidal Anti-Inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. [
           
   
    <content styleCode="italics">see Warnings and Precautions (
            
    
     <linkHtml href="#S5.1">5.1</linkHtml>)
           
   
    </content>].
          
  
   </content>
                           </item>
                        </list>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">NALFON
           
   
    <sup>®</sup> is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [
           
   
    <content styleCode="italics">see Contraindications (
            
    
     <linkHtml href="#S4">4</linkHtml>) and Warnings and precautions (
            
    
     <linkHtml href="#S5.1">5.1</linkHtml>)
           
   
    </content>].
          
  
   </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ff86dbd5-692a-43cf-b7c8-2a0742779128"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Gastrointestinal Bleeding, Ulceration, and Perforation</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [
           
   
    <content styleCode="italics">see Warnings and Precautions (
            
    
     <linkHtml href="#S5.2">5.2</linkHtml>)
           
   
    </content>].
          
  
   </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L2189c3d8-8986-4bcd-aac6-7ff087d053b3">
                     <id root="74443f8c-d669-4d3a-9a7f-95cd0cb35269"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text/>
                     <effectiveTime value="20160428"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S1a">
               <id root="9700c3b8-c3ae-4086-a589-9fedeb9112f4"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20160428"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col align="left" width="75%"/>
                           <col align="left" width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="left" colspan="2" valign="top">Boxed Warning</td>
                                 <td align="right" valign="top">4/2016</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="2" valign="top">Warnings and Precautions, Cardiovascular Thrombotic Events (
            
    
       <linkHtml href="#S5.1">5.1</linkHtml>)
           
   
      </td>
                                 <td align="right" valign="top">4/2016</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="2" valign="top">Warnings and Precautions, Heart Failure and Edema (
            
    
       <linkHtml href="#S5.5">5.5</linkHtml>)
           
   
      </td>
                                 <td align="right" valign="top">4/2016</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="1be266eb-e8a9-413e-9f05-af3200c843ea"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1.	INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>NALFON is indicated for:</paragraph>
                  <list listType="unordered">
                     <item>Relief of mild to moderate pain in adults.</item>
                     <item>Relief of the signs and symptoms of rheumatoid arthrites.</item>
                     <item>Relief of the signs and symptoms of osteoarthritis.</item>
                  </list>
                  <paragraph/>
               </text>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>NALFON is a nonsteroidal anti-inflammatory drug indicated for:</paragraph>
                        <list listType="unordered">
                           <item>Relief of mild to moderate pain in adults. (
          
  
     <linkHtml href="#S1">1</linkHtml>)
         
 
    </item>
                           <item>Relief of the signs and symptoms of rheumatoid arthritis. (
          
  
     <linkHtml href="#S1">1</linkHtml>)
         
 
    </item>
                           <item>Relief of the signs and symptoms of osteoarthritis. (
          
  
     <linkHtml href="#S1">1</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="eb011597-beb2-4b69-b8e1-9cced3f45bdd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2.	DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals (
          
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
         
 
    </item>
                           <item>Analgesia: For the treatment of mild to moderate pain, the recommended dosage is 200 mg given orally every 4 to 6 hours, as needed (
          
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
         
 
    </item>
                           <item>Rheumatoid Arthritis and Osteoarthritis: For the relief of signs and symptoms of rheumatoid arthritis or osteoarthritis the recommended dose is 400 to 600 mg given orally, 3 or 4 times a day. The dose should be tailored to the needs of the patient and may be increased or decreased depending on the severity of the symptoms. Dosage adjustments may be made after initiation of drug therapy or during exacerbations of the disease. Total daily dosage should not exceed 3,200 mg.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3559791f-7872-4ccd-9c86-21863f656ad0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Dosing Instructions</title>
                     <text>
                        <paragraph>Carefully consider the potential benefits and risks of NALFON and other treatment options before deciding to use NALFON. Use lowest effective dosage for the shortest duration consistent with individual patient treatment goals [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5">5</linkHtml>)
         
 
  </content>].
         
 
  <br/>Nalfon may be administered with meals or with milk. Although the total amount absorbed is not affected, peak blood levels are delayed and diminished.
         
 
  <br/>Patients with rheumatoid arthritis generally seem to require larger doses of Nalfon than do those with osteoarthritis. The smallest dose that yields acceptable control should be employed.
         
 
  <br/>Although improvement may be seen in a few days in many patients, an additional 2 to 3 weeks may be required to gauge the full benefits of therapy.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L0aaf7ba6-7712-4c00-88bb-4b63df6cf3c4">
                     <id root="3a6a14e4-c820-42c7-9593-f7e6fc60d817"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Analgesia</title>
                     <text>
                        <paragraph>For the treatment of mild to moderate pain, the recommended dosage is 200 mg given orally every 4 to 6 hours, as needed.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="fa08a476-d1a6-4302-892d-aaa5b6adedc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Rheumatoid Arthritis and Osteoarthritis</title>
                     <text>
                        <paragraph>For the relief of signs and symptoms of rheumatoid arthritis or osteoarthritis the recommended dose is 400 to 600 mg given orally, 3 or 4 times a day. The dose should be tailored to the needs of the patient and may be increased or decreased depending on the severity of the symptoms. Dosage adjustments may be made after initiation of drug therapy or during exacerbations of the disease. Total daily dosage should not exceed 3,200 mg.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="9df8695e-75e4-464a-8275-a008fd39f4ca"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3.	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Nalfon
       
 
  <sup>®</sup> (fenoprofen calcium) capsules:
      

 </paragraph>
                  <list listType="unordered">
                     <item>The 200 mg capsule is opaque yellow No. 97 cap and opaque white body, imprinted with "RX681" on the cap and body.</item>
                     <item>The 400 mg capsule is opaque green cap and opaque blue body, imprinted with "NALFON 400 mg" on the cap and "EP 123" on the body.</item>
                  </list>
               </text>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>NALFON (fenoprofen calcium) capsules: 200 mg and 400 mg (
         
 
    <linkHtml href="#S3">3</linkHtml>)
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="30899d36-0842-4e70-a6de-e70af55b0a07"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4.	CONTRAINDICATIONS</title>
               <text>
                  <paragraph>NALFON is contraindicated in the following patients:</paragraph>
                  <list listType="unordered">
                     <item>Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to fenoprofen or any components of the drug product [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.7">5.7</linkHtml>, 
         
   
    <linkHtml href="#S5.9">5.9</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.7">5.7</linkHtml>, 
         
   
    <linkHtml href="#S5.8">5.8</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>In the setting of coronary artery bypass graft (CABG) surgery [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.1">5.1</linkHtml>)
        
  
   </content>]
       
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Known hypersensitivity to fenoprofen or any components of the drug product (
          
  
     <linkHtml href="#S4">4</linkHtml>)
         
 
    </item>
                           <item>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (
          
  
     <linkHtml href="#S4">4</linkHtml>)
         
 
    </item>
                           <item>In the setting of CABG surgery (
          
  
     <linkHtml href="#S4">4</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="84d58d12-89ca-4eac-aae0-25b115811e08"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5.	WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Hepatotoxicity:</content> Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop (
          
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Hypertension:</content> Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure (
          
  
     <linkHtml href="#S5.4">5.4</linkHtml>, 
          
  
     <linkHtml href="#S7">7</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Heart Failure and Edema:</content> Avoid use of NALFON in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (
          
  
     <linkHtml href="#S5.5">5.5</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Renal Toxicity:</content> Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of NALFON in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (
          
  
     <linkHtml href="#S5.6">5.6</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Anaphylactic Reactions:</content> Seek emergency help if an anaphylactic reaction occurs (
          
  
     <linkHtml href="#S5.7">5.7</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Exacerbation of Asthma Related to Aspirin Sensitivity:</content> NALFON is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (
          
  
     <linkHtml href="#S5.8">5.8</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Serious Skin Reactions:</content> Discontinue NALFON at first appearance of skin rash or other signs of hypersensitivity (
          
  
     <linkHtml href="#S5.9">5.9</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Premature Closure of Fetal Ductus Arteriosus:</content> Avoid use in pregnant women starting at 30 weeks gestation (
          
  
     <linkHtml href="#S5.10">5.10</linkHtml>, 
          
  
     <linkHtml href="#S8.1">8.1</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Hematologic Toxicity:</content> Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia (
          
  
     <linkHtml href="#S5.11">5.11</linkHtml>, 
          
  
     <linkHtml href="#S7">7</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="5c1d893e-a3a8-46d0-8a89-b8ca67641a01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Cardiovascular Thrombotic Events</title>
                     <text>
                        <paragraph>Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.</paragraph>
                        <paragraph>To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.</paragraph>
                        <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as fenoprofen, increases the risk of serious gastrointestinal (GI) events [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.2">5.2</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Status Post Coronary Artery Bypass Graft (CABG) Surgery</content>
                           <br/>Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10–14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [
         
 
  <content styleCode="italics">see Contraindications (
          
  
   <linkHtml href="#S4">4</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Post-MI Patients</content>
                           <br/>Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.
        

 </paragraph>
                        <paragraph>Avoid the use of NALFON in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If NALFON is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.</paragraph>
                     </text>
                     <effectiveTime value="20150721"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="8a27da71-53a6-4ab5-8e8a-cb52520ea2c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Gastrointestinal Bleeding, Ulceration, and Perforation</title>
                     <text>
                        <paragraph>NSAIDs, including NALFON, cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDS. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Factors for GI Bleeding, Ulceration, and Perforation</content>
                           <br/>Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk of developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Strategies to Minimize the GI Risks in NSAID-treated Patients:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Use the lowest effective dosage for the shortest possible duration.</item>
                           <item>Avoid administration of more than one NSAID at a time.</item>
                           <item>Avoid use in patients at higher risk unless benefits are expected to outweigh theincreased risk of bleeding. For such patients, as well as those with active GIbleeding, consider alternate therapies other than NSAIDs.</item>
                           <item>Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.</item>
                           <item>If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue NALFON until a serious GI adverse event is ruled out.</item>
                           <item>In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding [
          
  
   <content styleCode="italics">see Drug Interactions (
           
   
    <linkHtml href="#S7">7</linkHtml>)
          
  
   </content>].
         
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="c8272aa6-aa59-40c5-bf00-484619314af7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hepatotoxicity</title>
                     <text>
                        <paragraph>Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported.</paragraph>
                        <paragraph>Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs including fenoprofen.</paragraph>
                        <paragraph>Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue NALFON immediately, and perform a clinical evaluation of the patient.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="8d9872c7-272f-4fde-b74c-1e7aa8b97db7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypertension</title>
                     <text>
                        <paragraph>NSAIDs, including NALFON, can lead to new onset of hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [
         
 
  <content styleCode="italics">see Drug Interactions (
          
  
   <linkHtml href="#S7">7</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                        <paragraph>Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="f079d1f5-1f21-472f-85f9-1b8b0c5e348c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Heart Failure and Edema</title>
                     <text>
                        <paragraph>The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.</paragraph>
                        <paragraph>Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of fenoprofen may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [
         
 
  <content styleCode="italics">see Drug Interactions (
          
  
   <linkHtml href="#S7">7</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                        <paragraph>Avoid the use of NALFON in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If NALFON is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.</paragraph>
                     </text>
                     <effectiveTime value="20150710"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="a57d478b-c92d-4c4b-aced-586f61a1372a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Renal Toxicity and Hyperkalemia</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Renal Toxicity</content>
                           <br/>Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.
        

 </paragraph>
                        <paragraph>Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</paragraph>
                        <paragraph>No information is available from controlled clinical studies regarding the use of NALFON in patients with advanced renal disease. The renal effects of NALFON may hasten the progression of renal dysfunction in patients with pre-existing renal disease.</paragraph>
                        <paragraph>Correct volume status in dehydrated or hypovolemic patients prior to initiating NALFON. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of NALFON [
         
 
  <content styleCode="italics">see Drug Interactions (
          
  
   <linkHtml href="#S7">7</linkHtml>)
         
 
  </content>]. Avoid the use of NALFON in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If NALFON is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyperkalemia</content>
                           <br/>Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="af0277d5-40dc-4f6d-a2ca-00b05025808f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Anaphylactic Reactions</title>
                     <text>
                        <paragraph>Fenoprofen has been associated with anaphylactic reactions in patients with and without known hypersensitivity to fenoprofen and in patients with aspirin-sensitive asthma [
         
 
  <content styleCode="italics">see Contraindications (
          
  
   <linkHtml href="#S4">4</linkHtml>) and Warnings and Precautions (
          
  
   <linkHtml href="#S5.8">5.8</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                        <paragraph>Seek emergency help if an anaphylactic reaction occurs.</paragraph>
                     </text>
                     <effectiveTime value="20150710"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="a5b93e73-56f2-4d7a-b558-19287ed15e19"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Exacerbation of Asthma Related to Aspirin Sensitivity</title>
                     <text>
                        <paragraph>A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, NALFON is contraindicated in patients with this form of aspirin sensitivity [
         
 
  <content styleCode="italics">see Contraindications (
          
  
   <linkHtml href="#S4">4</linkHtml>)
         
 
  </content>]. When NALFON is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20150710"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="5161edb1-05a1-44e5-bba4-0e50d0f7a51a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Serious Skin Reactions</title>
                     <text>
                        <paragraph>NSAIDs, including fenopropfen, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of NALFON at the first appearance of skin rash or any other sign of hypersensitivity.</paragraph>
                        <paragraph>NALFON is contraindicated in patients with previous serious skin reactions to NSAIDs [
         
 
  <content styleCode="italics">see Contraindications (
          
  
   <linkHtml href="#S4">4</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20150714"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="bf7922e9-8d4c-434e-9969-5fc593440da3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Premature Closure of Fetal Ductus Arteriosus</title>
                     <text>
                        <paragraph>Fenoprofen may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including NALFON, in pregnant women starting at 30 weeks of gestation (third trimester) [
         
 
  <content styleCode="italics">see Use in Specific Populations (
          
  
   <linkHtml href="#S8.1">8.1</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20150710"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="20f21a8d-7e03-45bf-910f-4e4c71e683bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Hematologic Toxicity</title>
                     <text>
                        <paragraph>Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with NALFON has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.</paragraph>
                        <paragraph>NSAIDs, including NALFON, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [
         
 
  <content styleCode="italics">see Drug Interactions (
          
  
   <linkHtml href="#S7">7</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="8793f467-23ce-44ba-8b84-d9c6da462231"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Masking of Inflammation and Fever</title>
                     <text>
                        <paragraph>The pharmacological activity of NALFON in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.</paragraph>
                     </text>
                     <effectiveTime value="20150710"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="76580050-c7ec-4296-a077-261dfcc6c90d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Laboratory Monitoring</title>
                     <text>
                        <paragraph>Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.2">5.2</linkHtml>, 
          
  
   <linkHtml href="#S5.3">5.3</linkHtml>, 
          
  
   <linkHtml href="#S5.6">5.6</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20150721"/>
                  </section>
               </component>
               <component>
                  <section ID="L46395ce7-b189-42c3-adba-85860579e5aa">
                     <id root="a878037d-71c9-492c-9d9d-85953cb67075"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Ocular Effects</title>
                     <text>
                        <paragraph>Studies to date have not shown changes in the eyes attributable to the administration of NALFON. However, adverse ocular effects have been observed with other anti-inflammatory drugs. Eye examinations, therefore, should be performed if visual disturbances occur in patients taking NALFON.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf27cf97d-11f6-42d2-bf8b-090883a008aa">
                     <id root="d5432dd4-b47b-42ae-a7df-e7322ab7a77b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.15 Central Nervous System Effects</title>
                     <text>
                        <paragraph>Caution should be exercised by patients whose activities require alertness if they experience CNS side effects while taking NALFON.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L80f5664c-728a-4132-8438-a5f996d3c2d5">
                     <id root="41751636-1303-4208-8d9e-b2c2b4ecefff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.16 Impact on Hearing</title>
                     <text>
                        <paragraph>Since the safety of NALFON has not been established in patients with impaired hearing, these patients should have periodic tests of auditory function during prolonged therapy with NALFON.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="5512a568-d2b2-49ff-b99f-0822b9c829a2"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6.	ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Cardiovascular Thrombotic Events [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.1">5.1</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>GI Bleeding, Ulceration and Perforation [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.2">5.2</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>Hepatotoxicity [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.3">5.3</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>Hypertension [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.4">5.4</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>Heart Failure and Edema [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.5">5.5</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>Renal Toxicity and Hyperkalemia [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.6">5.6</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>Anaphylactic Reactions [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.7">5.7</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>Serious Skin Reactions [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.9">5.9</linkHtml>)
        
  
   </content>]
       
 
  </item>
                     <item>Hematologic Toxicity [
        
  
   <content styleCode="italics">see Warnings and Precautions (
         
   
    <linkHtml href="#S5.11">5.11</linkHtml>)
        
  
   </content>]
       
 
  </item>
                  </list>
                  <paragraph/>
               </text>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence ≥ 5%) are Dyspepsia, headache, somnolence, nausea, dizziness, constipation, nervousness, asthenia, and peripheral edema.</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Xspire Pharma at 1-601-990-9497 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="2007d498-09c5-4bff-99f4-db0b33ce52d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>During clinical studies for rheumatoid arthritis, osteoarthritis, or mild to moderate pain and studies of pharmacokinetics, complaints were compiled from a checklist of potential adverse reactions, and the following data emerged. These encompass observations in 6,786 patients, including 188 observed for at least 52 weeks. For comparison, data are also presented from complaints received from the 266 patients who received placebo in these same trials. During short-term studies for analgesia, the incidence of adverse reactions was markedly lower than that seen in longer-term studies.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Adverse Drug Reactions Reported in &gt;1% of Patients During Clinical Trials</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive System</content> — During clinical trials with Nalfon, the most common adverse reactions were gastrointestinal in nature and occurred in 20.8% of patients receiving Nalfon as compared to 16.9% of patients receiving placebo. In descending order of frequency, these reactions included dyspepsia (10.3% Nalfon vs. 2.3% placebo), nausea (7.7% vs. 7.1%), constipation (7% vs. 1.5%), vomiting (2.6% vs. 1.9%), abdominal pain (2% vs. 1.1%), and diarrhea (1.8% vs. 4.1%). The drug was discontinued because of adverse gastrointestinal reactions in less than 2% of patients during premarketing studies.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System</content> — The most frequent adverse neurologic reactions were headache (8.7% vs. 7.5%) and somnolence (8.5% vs. 6.4%). Dizziness (6.5% vs. 5.6%), tremor (2.2% vs. 0.4%), and confusion (1.4% vs. none) were noted less frequently. Nalfon was discontinued in less than 0.5% of patients because of these side effects during premarketing studies.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Appendages</content>— Increased sweating (4.6% vs. 0.4%), pruritus (4.2% vs. 0.8%), and rash (3.7% vs. 0.4%) were reported. Nalfon was discontinued in about 1% of patients because of an adverse effect related to the skin during premarketing studies.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses</content> — Tinnitus (4.5% vs. 0.4%), blurred vision (2.2% vs. none), and decreased hearing (1.6% vs. none) were reported. Nalfon was discontinued in less than 0.5% of patients because of adverse effects related to the special senses during premarketing studies.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular</content> — Palpitations (2.5% vs. 0.4%). Nalfon was discontinued in about 0.5% of patients because of adverse cardiovascular reactions during premarketing studies.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Miscellaneous</content> — Nervousness (5.7% vs. 1.5%), asthenia (5.4% vs. 0.4%), peripheral edema (5.0% vs. 0.4%), dyspnea (2.8% vs. none), fatigue (1.7% vs. 1.5%), upper respiratory infection (1.5% vs. 5.6%), and nasopharyngitis (1.2% vs. none).
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Adverse Drug Reactions Reported in &lt;1% of Patients During Clinical Trials</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive System</content>—Gastritis, peptic ulcer with/without perforation, gastrointestinal hemorrhage, anorexia, flatulence, dry mouth, and blood in the stool. Increases in alkaline phosphatase, LDH, SGOT, jaundice, and cholestatic hepatitis, aphthous ulcerations of the buccal mucosa, metallic taste, and pancreatitis.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular</content>—Atrial fibrillation, pulmonary edema, electrocardiographic changes, and supraventricular tachycardia.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Genitourinary Tract</content>—Renal failure, dysuria, cystitis, hematuria, oliguria, azotemia, anuria, interstitial nephritis, nephrosis, and papillary necrosis.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity</content>—Angioedema (angioneurotic edema).
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic</content>—Purpura, bruising, hemorrhage, thrombocytopenia, hemolytic anemia, aplastic anemia, agranulocytosis, and pancytopenia.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System</content>—Depression, disorientation, seizures, and trigeminal neuralgia.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses</content>—Burning tongue, diplopia, and optic neuritis.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Appendages</content>—Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, and alopecia.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Miscellaneous</content>—Anaphylaxis, urticaria, malaise, insomnia, tachycardia, personality change, lymphadenopathy, mastodynia, and fever.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="1a366798-5e69-4063-a839-46792db489c3"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7.	DRUG INTERACTIONS</title>
               <text>
                  <paragraph>See Table 1 for clinically significant drug interactions with fenoprophen.</paragraph>
                  <table width="80%">
                     <caption>Table 1: Clinically Significant Drug Interactions with Fenoprofen</caption>
                     <col align="left" valign="middle" width="20%"/>
                     <col align="left" valign="middle" width="80%"/>
                     <tbody>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Drugs That Interfere with Hemostasis</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">
                              <list listType="unordered">
                                 <item>Fenoprofen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of fenoprofen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</item>
                                 <item>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">Monitor patients with concomitant use of NALFON with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [
          
    
     <content styleCode="italics">see Warnings and Precautions (
           
     
      <linkHtml href="#S5.11">5.11</linkHtml>)
          
    
     </content>].
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Aspirin</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [
          
    
     <content styleCode="italics">see Warnings and Precautions (
           
     
      <linkHtml href="#S5.2">5.2</linkHtml>)
          
    
     </content>].
         
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">
                              <paragraph>Concomitant use of NALFON and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [
           
     
      <content styleCode="italics">see Warnings and Precautions (
            
      
       <linkHtml href="#S5.11">5.11</linkHtml>)
           
     
      </content>].
          
    
     </paragraph>
                              <paragraph>NALFON is not a substitute for low dose aspirin for cardiovascular protection.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">
                              <list listType="unordered">
                                 <item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</item>
                                 <item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>During concomitant use of NALFON and ACE-inhibitors, ARBs, or betablockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</item>
                                 <item>During concomitant use of NALFON ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [
            
      
       <content styleCode="italics">see Warnings and Precautions (
             
       
        <linkHtml href="#S5.6">5.6</linkHtml>)
            
      
       </content>].
           
     
      </item>
                                 <item>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Diuretics</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">During concomitant use of NALFON with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [
          
    
     <content styleCode="italics">see Warnings and Precautions (
           
     
      <linkHtml href="#S5.6">5.6</linkHtml>)
          
    
     </content>].
         
   
    </td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Digoxin</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">The concomitant use of fenoprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">During concomitant use of NALFON and digoxin, monitor serum digoxin levels.</td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Lithium</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">During concomitant use of NALFON and lithium, monitor patients for signs of lithium toxicity.</td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Methotrexate</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">During concomitant use of NALFON and methotrexate, monitor patients for methotrexate toxicity.</td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Cyclosporine</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">Concomitant use of NALFON and cyclosporine may increase cyclosporine’s nephrotoxicity.</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">During concomitant use of NALFON and cyclosporine, monitor patients for signs of worsening renal function.</td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">NSAIDs and Salicylates</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">Concomitant use of fenoprofen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [
          
    
     <content styleCode="italics">see Warnings and Precautions (
           
     
      <linkHtml href="#S5.2">5.2</linkHtml>)
          
    
     </content>].
         
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">The concomitant use of fenoprofen with other NSAIDs or salicylates is not recommended.</td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Pemetrexed</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">Concomitant use of NALFON and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">
                              <paragraph>During concomitant use of NALFON and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.</paragraph>
                              <paragraph>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.</paragraph>
                              <paragraph>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Phenobarbital</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">When phenobarbital is added to or withdrawn from treatment, dosage adjustment of NALFON may be required.</td>
                        </tr>
                        <tr styleCode="Botrule First Last">
                           <th align="left" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Hydantoins, sulfonamides, or sulfonylureas</content>
                           </th>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" styleCode="Botrule Rrule">In vitro studies have shown that fenoprofen, because of its affinity for albumin, may displace from their binding sites other drugs that are also albumin bound, and this may lead to drug interactions. Theoretically, fenoprofen could likewise be displaced.</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" styleCode="Rrule">Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Drugs that Interfere with Hemostasis (e.g. warfarin, aspirin, SSRIs/SNRIs):</content> Monitor patients for bleeding who are concomitantly taking NALFON with drugs that interfere with hemostasis. Concomitant use of NALFON and analgesic doses of aspirin is not generally
          
  
     <br/>recommended (
          
  
     <linkHtml href="#S7">7</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers:</content> Concomitant use with NALFON may diminish the antihypertensive effect of these drugs. Monitor blood pressure (
          
  
     <linkHtml href="#S7">7</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">ACE Inhibitors and ARBs:</content> Concomitant use with NALFON in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function (
          
  
     <linkHtml href="#S7">7</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Diuretics:</content> NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects (
          
  
     <linkHtml href="#S7">7</linkHtml>)
         
 
    </item>
                           <item>
                              <content styleCode="underline">Digoxin:</content> Concomitant use with NALFON can increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels (
          
  
     <linkHtml href="#S7">7</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L289c9943-166f-419c-b393-395e8610fa4d">
                     <id root="71e2c238-1b89-44fd-afdc-6ff19a5368f9"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug/Laboratory Test Interactions</content>
                        </paragraph>
                        <paragraph>Amerlex-M kit assay values of total and free triiodothyronine in patients receiving Nalfon have been reported as falsely elevated on the basis of a chemical cross-reaction that directly interferes with the assay. Thyroid-stimulating hormone, total thyroxine, and thyrotropin-releasing hormone response are not affected. Thus, results of the Amerlex-M kit assay should be interpreted with caution in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="571a8b50-370c-49e1-b8af-f11159ccf068"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8.	USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20160429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy:</content> Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation (
         
 
    <linkHtml href="#S5.10">5.10</linkHtml>, 
         
 
    <linkHtml href="#S8.1">8.1</linkHtml>)
        

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility:</content> NSAIDs are associated with reversible infertility. Consider withdrawal of NALFON in women who have difficulties conceiving (
         
 
    <linkHtml href="#S8.3">8.3</linkHtml>)
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="dd7f7a0b-5f1e-45ce-aab4-815fd33c59f2"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Use of NSAIDs, including NALFON, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including NALFON, in pregnant women starting at 30 weeks of gestation (third trimester).
        

 </paragraph>
                        <paragraph>There are no adequate and well-controlled studies of NALFON in pregnant women. Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In the general U.S. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2-4% for major malformations, and 15-20% for pregnancy loss.</paragraph>
                        <paragraph>In animal reproduction studies, embryo-fetal lethality and skeletal abnormalities were noted in offspring of pregnant rabbits following oral administration of fenoprofen during organogenesis at 0.6 times the maximum human daily dose of 3200 mg/day. However, there were no major malformations noted following oral administration of fenoprofen calcium to pregnant rats and rabbits during organogenesis at exposures up to 0.3 and 0.6 times the maximum human daily dose of 3200 mg/day.</paragraph>
                        <paragraph>Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as fenoprofen, resulted in increased pre- and post-implantation loss.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                           <br/>
                           <content styleCode="italics">Labor or Delivery</content>
                           <br/>There are no studies on the effects of NALFON during labor or delivery. In animal studies, NSAIDS, including fenoprofen, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="italics">Human Data</content>
                           <br/>There are no adequate and well-controlled studies of NALFON in pregnant women. Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal data</content>
                           <br/>Pregnant rats were treated with fenoprofen using oral doses of 50 or 100 mg/kg (0.15 times and 0.3 times the maximum human daily dose (MHDD) of 3200 mg/day based on body surface area comparison) during the period of organogenesis. No major malformations were noted and there was no evidence of maternal toxicity at these doses, however, the exposures were below the exposures that will occur in humans.
         
 
  <br/>Pregnant rabbits were treated with fenoprofen using oral doses of 50 or 100 mg/kg (0.3 times and 0.6 times the MHDD of 3200 mg/day based on body surface area comparison) during the period of organogenesis. Maternal toxicity (mortality) was noted in the high dose animals. Although no major malformations were noted, there was an increased incidence of embryo-fetal lethality and skeletal abnormalities were present at 0.6 times the MHDD.
         
 
  <br/>Pregnant rats were treated from Gestation Day 14 through Post-Natal Day 20 with oral doses of fenoprofen of 6.25, 12.5, 25, 50, or 100 mg/kg (0.02, 0.04, 0.08, 0.15, or 0.3 times the MDD of 3200 mg/day based on body surface area comparison). All doses produced significant toxicity, including vaginal bleeding, prolonged parturition, increased stillbirths, and maternal deaths.
         
 
  <br/>Pregnant rats were treated from Gestation Day 6 through Gestation Day 19 and Post Partum Day 1 to 20 (excluding parturition) with an oral dose of fenoprofen of 100 mg/kg (0.3 times the MDD of 3200 mg/day based on body surface area comparison) demonstrated only a small increase in the incidence of impaired parturition despite the presence of maternal toxicity (gastrointestinal ulceration and renal toxicity).
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="78f1991d-6745-4b62-8c63-5f87afff4532"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>In a published study, after a dose of 600 mg every 6 hours for 4 days in postpartum mothers, breastmilk fenoprofen levels were reportedly 1.6% of those in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NALFON and any potential adverse effects on the breastfed infant from the NALFON or from the underlying maternal condition.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="3e344d49-10f9-408e-acce-0bc57f861c8b"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                           <br/>
                           <content styleCode="italics">Females</content>
                           <br/>Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including NALFON, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandinmediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including NALFON, in women who have difficulties conceiving or who are undergoing investigation of infertility.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20150714"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="3a8cb8f2-fa2f-4749-a627-29a622ae28dc"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients under the age of 18 have not been established.                  
                </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="1d76e1cb-fc0e-4387-b79f-bb6f269227a0"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use</title>
                     <text>
                        <paragraph>Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.1">5.1</linkHtml>, 
          
  
   <linkHtml href="#S5.2">5.2</linkHtml>, 
          
  
   <linkHtml href="#S5.3">5.3</linkHtml>, 
          
  
   <linkHtml href="#S5.6">5.6</linkHtml>, 
          
  
   <linkHtml href="#S5.13">5.13</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20150714"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="fa0f880e-bb89-4b14-8bbd-5f00f67128be"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10.	OVERDOSAGE</title>
               <text>
                  <paragraph>Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [
       
 
  <content styleCode="italics">see Warnings and Precautions (
        
  
   <linkHtml href="#S5.1">5.1</linkHtml>, 
        
  
   <linkHtml href="#S5.2">5.2</linkHtml>, 
        
  
   <linkHtml href="#S5.4">5.4</linkHtml>, 
        
  
   <linkHtml href="#S5.6">5.6</linkHtml>)
       
 
  </content>].
      

 </paragraph>
                  <paragraph>Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</paragraph>
                  <paragraph>For additional information about overdosage treatment contact a poison control center (1-800-222-1222).</paragraph>
               </text>
               <effectiveTime value="20160429"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="b52aecff-922c-4139-aed7-aa14ef822c1a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11.	DESCRIPTION</title>
               <text>
                  <paragraph>NALFON (fenoprofen calcium, USP) capsules is a nonsteroidal, anti-inflammatory drug available in 200 mg and 400 mg capsule form for oral administration.</paragraph>
                  <paragraph>The 200 mg capsule is opaque yellow No. 97 cap and opaque white body, imprinted with “RX681” on the cap and body.</paragraph>
                  <paragraph>The 400 mg capsule is opaque green cap and opaque blue body, imprinted with “NALFON 400 mg" on the cap and “EP 123” on the body.</paragraph>
                  <paragraph>The chemical name is Benzenaecetic acid, α-methyl-3-phenoxy-, calcium salt dihydrate, (±)-. The molecular weight is 558.65. Its molecular formula is C
       
 
  <sub>30</sub>H
       
 
  <sub>26</sub>CaO
       
 
  <sub>6</sub>•2H
       
 
  <sub>2</sub>O, and it has the following chemical structure.
      

 </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Fenoprofen Calcium is an arylacetic acid derivative. It is a white crystalline powder. At 25°C, it dissolves to a 15 mg/mL solution in alcohol (95%). It is slightly soluble in water and insoluble in benzene.The pKa of fenoprofen calcium is 4.5 at 25°C.</paragraph>
                  <paragraph>Nalfon capsules contain fenoprofen calcium as the dihydrate in an amount equivalent to 200 mg (0.826 mmol) or 400 mg (1.65 mmol) of fenoprofen.</paragraph>
                  <paragraph>Inactive ingredients in Nalfon capsules are crospovidone, magnesium stearate, sodium lauryl sulfate, and talc. In addition, the 200 mg capsules contain gelatin, titanium dioxide, yellow iron oxide, and red iron oxide, and the 400 mg capsules contain gelatin, D&amp;C Yellow #10, FD&amp;C Blue #1, FD&amp;C Red #40, FD&amp;C Yellow #6, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20160429"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="0354e39b-32d5-4e8a-916c-7af14fe96b43"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12.	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20160429"/>
               <component>
                  <section ID="S12.1">
                     <id root="bba10655-ee98-45d7-8c4b-dd58855fec17"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Fernoprofen has analgesic, anti-inflammatory, and antipyretic properties.</paragraph>
                        <paragraph>The mechanism of action of NALFON, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).</paragraph>
                        <paragraph>Fenoprofen is a potent inhibitor of prostaglandin synthesis in vitro. Fenoprofen concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because fenoprofen is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="bbcc0704-cb5a-4040-ace5-524079b80430"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                           <br/>Under fasting conditions, fenoprofen is rapidly absorbed, and peak plasma levels of 50 mcg/L are achieved within 2 hours after oral administration of 600 mg doses. Good dose proportionality was observed between 200 and 600 mg doses in fasting male volunteers.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                           <br/>Fenoprofen is highly bound (99%) to albumin.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                           <br/>The plasma half-life is approximately 3 hours.
                
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                           <br/>About 90% of a single oral dose is eliminated within 24 hours as fenoprofen glucuronide and 4'-hydroxyfenoprofen glucuronide, the major urinary metabolites of fenoprofen.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gertatrics</content>
                           <br/>Peak plasma levels of fenoprofen in normal elderly volunteers were similar to those observed in normal young volunteers. Elderly volunteers had a mean plasma clearance of 2.2 L/hour while plasma clearance of fenoprofen in normal young volunteers ranged from 3 to 3.5 L/hour. The overall elimination rate constant, plasma half-life and ratio of renal to nonrenal clearance of fenoprofen was the same in elderly and young volunteers. The 30 to 60% decrease in plasma clearance is due to a decrease in the volume of distribution in the body.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                           <br/>
                           <content styleCode="italics">Aspirin:</content> When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. The clinical significance of this interaction is not known. See Table 1 for clinically significant drug interactions of NSAIDs with aspirin [
         
 
  <content styleCode="italics">see Drug Interactions (
          
  
   <linkHtml href="#S7">7</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Antacid:</content> The concomitant administration of antacid (containing both aluminum and magnesium hydroxide) does not interfere with absorption of fenoprofen.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="ef4529ad-1e03-4861-b9bb-8f599b9d5137"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20160429"/>
               <component>
                  <section ID="S13.1">
                     <id root="2c4775e4-8a8f-4c80-bf28-3f56f9900a58"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                           <br/>Long-term studies in animals to evaluate the carcinogenic potential of fenoprofen have not been conducted.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                           <br/>Studies to evaluate the genotoxic potential of fenoprofen have not been conducted.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                           <br/>Female and Male rats were treated with 60 to 70 mg/kg/day or 120 to 150 mg/kg/day fenoprofen calcium via the diet (approximately 0.2 or 0.4 times the maximum human daily dose of 3200 mg/day based on body surface area comparison, respectively). Male rats were treated from 77 days prior to mating and during mating. Female rats were treated from 14 days prior to mating and through gestation. Pregnancy rates were slightly reduced in the low and high dose groups compared to controls. There was no adverse effect on implantations, resorptions, or live fetuses.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="205ee2cd-70da-4811-b1db-ab8213aa8a20"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14.	CLINICAL STUDIES</title>
               <text>
                  <paragraph>NALFON is a nonsteroidal, anti-inflammatory, antiarthritic drug that also possesses analgesic and antipyretic activities. Its exact mode of action is unknown, but it is thought that prostaglandin synthetase inhibition is involved.</paragraph>
                  <paragraph>Results in humans demonstrate that fenoprofen has both anti-inflammatory and analgesic actions. The emergence and degree of erythemic response were measured in adult male volunteers exposed to ultraviolet irradiation. The effects of NALFON, aspirin, and indomethacin were each compared with those of a placebo. All 3 drugs demonstrated antierythemic activity.</paragraph>
                  <paragraph>In all patients with rheumatoid arthritis, the anti-inflammatory action of NALFON has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). The anti-inflammatory action of NALFON has also been evidenced by increased mobility (i.e., a decrease in the number of joints having limited motion).</paragraph>
                  <paragraph>The use of NALFON in combination with gold salts or corticosteroids has been studied in patients with rheumatoid arthritis. The studies, however, were inadequate in demonstrating whether further improvement is obtained by adding NALFON to maintenance therapy with gold salts or steroids. Whether or not NALFON used in conjunction with partially effective doses of a corticosteroid has a “steroid-sparing” effect is unknown.</paragraph>
                  <paragraph>In patients with osteoarthritis, the anti-inflammatory and analgesic effects of NALFON have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints.</paragraph>
                  <paragraph>In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown NALFON to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with NALFON than in aspirin-treated patients. It is not known whether NALFON causes less peptic ulceration than does aspirin.</paragraph>
                  <paragraph>In patients with pain, the analgesic action of Nalfon has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect.</paragraph>
               </text>
               <effectiveTime value="20160429"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="22ef84e0-f8fa-4da8-a3ae-dab437bafa19"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16.	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Product:    63629-7515</paragraph>
                  <paragraph>NDC:    63629-7515-1   30 CAPSULE in a BOTTLE</paragraph>
                  <paragraph>NDC:    63629-7515-2   90 CAPSULE in a BOTTLE</paragraph>
                  <paragraph>NDC:    63629-7515-3   28 CAPSULE in a BOTTLE</paragraph>
                  <paragraph>NDC:    63629-7515-4   60 CAPSULE in a BOTTLE</paragraph>
                  <paragraph>NDC:    63629-7515-5   120 CAPSULE in a BOTTLE</paragraph>
               </text>
               <effectiveTime value="20190807"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="b90fbb5d-ddd8-435a-8b20-bc4564fcb050"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17. PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed. Inform patients, families, or their caregivers of the following information before initiating therapy with NALFON and periodically during the course of ongoing therapy.</paragraph>
               </text>
               <effectiveTime value="20160429"/>
               <component>
                  <section ID="Lad2861c7-f9b5-4cec-9c22-30226ac7a88f">
                     <id root="dcff9dec-efde-405e-a3ba-1dfa8e47bfbe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiovascular Thrombotic Events</content>Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health care provider immediately [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.1">5.1</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L8576b34b-9547-42b3-ae2c-c56798391b31">
                     <id root="e5e7d263-3b68-4b8a-ab15-d311b4ee56bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Gastrointestinal Bleeding, Ulceration, and Perforation</content>
                           <br/>Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their health care provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for and the signs and symptoms of GI bleeding [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.2">5.2</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L99d42991-8698-452d-983d-a6f1b2607af0">
                     <id root="98abd50d-4e7f-43f3-bbb0-2bd130976089"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                           <br/>Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, diarrhea, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, instruct patients to stop NALFON and seek immediate medical therapy [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.3">5.3</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L956aac8f-e700-43bc-9b1b-6d63ee2ff372">
                     <id root="23f4da1f-d984-4d77-961c-6cc69dbaf79f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Heart Failure and Edema</content>
                           <br/>Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.5">5.5</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="Laa7dd104-43f7-4064-b66e-1031f1003f20">
                     <id root="1dea5f62-d3e3-4d09-aec7-4c2cc646b8bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Anaphylactic Reactions</content>
                           <br/>Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [
         
 
  <content styleCode="italics">see Contraindications (
          
  
   <linkHtml href="#S4">4</linkHtml>) and Warnings and Precautions (
          
  
   <linkHtml href="#S5.7">5.7</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L18ac3ea4-0f91-4751-bffc-c47d6323d390">
                     <id root="1b26b7ad-02e8-46f4-9c6a-acdac7be6e4d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Skin Reactions</content>
                           <br/>Advise patients to stop NALFON immediately if they develop any type of rash and to contact their healthcare provider as soon as possible [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.9">5.9</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L55bd6708-50a6-4fd4-972d-42b3eb178470">
                     <id root="b2c783e3-0dd9-42a8-88d4-8c958568c19e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Female Fertility</content>
                           <br/>Advise females of reproductive potential who desire pregnancy that NSAIDs, including NALFON, may be associated with a reversible delay in ovulation [
         
 
  <content styleCode="italics">see Use in Specific Populations (
          
  
   <linkHtml href="#S8.3">8.3</linkHtml>)
         
 
  </content>]
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L5c7172e9-870e-45d3-bf35-f54c06fd1dd2">
                     <id root="bd272e97-7af4-41c6-bf83-818a0fe03861"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Fetal Toxicity</content>
                           <br/>Inform pregnant women to avoid use of NALFON and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.10">5.10</linkHtml>) and Use in Specific Populations (
          
  
   <linkHtml href="#S8.1">8.1</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L3523ddbc-0a29-4b9a-9999-28b7ab7dc477">
                     <id root="d7304c7e-a57e-4266-81ec-d2cab64a20f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Avoid Concomitant Use of NSAIDs</content>
                           <br/>Inform patients that the concomitant use of NALFON with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [
         
 
  <content styleCode="italics">see Warnings and Precautions (
          
  
   <linkHtml href="#S5.2">5.2</linkHtml>) and Drug Interactions (
          
  
   <linkHtml href="#S7">7</linkHtml>)
         
 
  </content>]. Alert patients that NSAIDs may be present in “over the counter” medications for treatment of colds, fever, or insomnia.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="L2513a25f-af09-4b6c-b055-cbf5172d1140">
                     <id root="e59271cc-3796-445f-9a51-2ff725169388"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Use of NSAIDS and Low-Dose Aspirin</content>
                           <br/>Inform patients not to use low-dose aspirin concomitantly with NALFON until they talk to their healthcare provider [
         
 
  <content styleCode="italics">see Drug Interactions (
          
  
   <linkHtml href="#S7">7</linkHtml>)
         
 
  </content>].
        

 </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb7847e97-8885-40f2-8f05-f151c21dfa86">
                     <id root="db06f762-c0b0-4dd0-a728-dcceacdee483"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Manufactured for:</content>
                           <br/>
                           <content styleCode="bold">Xspire Pharma</content>
                           <br/>Ridgeland, MS. 39157
        

 </paragraph>
                        <paragraph>Issued: 04/ 2016</paragraph>
                     </text>
                     <effectiveTime value="20160429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17.11">
               <id root="d9e2d83b-ac80-41c3-9f0e-a02abd2b3e3f"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>
                  <content styleCode="underline">Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about medicines called Nonsteroidal Antiinflammatory Drugs (NSAIDs)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAIDs can cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Increased risk of a heart attack or stroke that can lead to death. </content>This risk may happen early in treatment and may increase:
        
  
   <list listType="unordered">
                           <item>with increasing doses of NSAIDs</item>
                           <item>with longer use of NSAIDs</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Do not take NSAIDs right before or after a heart surgery called a “coronary artery bypass graft (CABG)."</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines:</content>
                        <list listType="unordered">
                           <item>anytime during use</item>
                           <item>without warning symptoms</item>
                           <item>that may cause death</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The risk of getting an ulcer or bleeding increases with:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <list listType="unordered">
                           <item>past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs</item>
                           <item>taking medicines called “corticosteroids”, “anticoagulants”, “SSRIs”, or “SNRIs”</item>
                           <item>increasing doses of NSAIDs</item>
                           <item>longer use of NSAIDs</item>
                           <item>smoking</item>
                           <item>drinking alcohol</item>
                           <item>older age</item>
                           <item>poor health</item>
                           <item>advanced liver disease</item>
                           <item>bleeding problems</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">NSAIDs should only be used:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <list listType="unordered">
                           <item>exactly as prescribed</item>
                           <item>at the lowest dose possible for your treatment</item>
                           <item>for the shortest time needed</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are NSAIDs?</content>
                  </paragraph>
                  <paragraph>NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take NSAIDs?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take NSAIDs:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs</item>
                     <item>right before or after heart bypass surgery.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before taking NSAIDS, tell your healthcare provider about all of your medical conditions, including if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>have liver or kidney problems</item>
                     <item>have high blood pressure</item>
                     <item>have asthma</item>
                     <item>are pregnant or plan to become pregnant. Talk to your healthcare provivder if you are considering taking NSAIDs during pregnancy. 
        
  
   <content styleCode="bold">You should not take NSAIDs after 29 weeks of pregnancy.</content>
                     </item>
                     <item>are breastfeeding or plan to breast feed.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements.</content> NSAIDs and some other medicines can interact with each other and cause serious side effects. 
       
 
  <content styleCode="bold">Do not start taking any new medicine without talking to your healthcare provider first.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of NSAIDs?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAIDs can cause serious side effects, including:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">See “What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?"</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>new or worse high blood pressure</item>
                     <item>heart failure</item>
                     <item>liver problems including liver failure</item>
                     <item>kidney problems including kidney failure</item>
                     <item>low red blood cells (anemia)</item>
                     <item>life-threatening skin reactions</item>
                     <item>life-threatening allergic reactions</item>
                     <item>
                        <content styleCode="bold">Other side effects of NSAIDs include: </content>stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness
       
 
  </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Get emergency help right away if you get any of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>shortness of breath or trouble breathing</item>
                     <item>chest pain</item>
                     <item>weakness in one part or side of your body</item>
                     <item>slurred speech</item>
                     <item>swelling of the face or throat</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>nausea</item>
                     <item>more tired or weaker than usual</item>
                     <item>diarrhea</item>
                     <item>itching</item>
                     <item>your skin or eyes look yellow</item>
                     <item>indigestion or stomach pain</item>
                     <item>flu-like symptoms</item>
                     <item>vomit blood</item>
                     <item>there is blood in your bowel movement or it is black and sticky like tar</item>
                     <item>unusual weight gain</item>
                     <item>skin rash or blisters with fever</item>
                     <item>swelling of the arms, legs, hands and feet</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you take too much of your NSAID, call your healthcare provider or get medical help right away. </content>These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs.
      

 </paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Other information about NSAIDs</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.</item>
                     <item>Some NSAIDs are sold in lower doses without a prescription (over-the counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of NSAIDs</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Manufactured for:</content>
                     <br/>
                     <content styleCode="bold">Xspire Pharma</content>
                     <br/>Ridgeland, MS. 39157
      

 </paragraph>
                  <paragraph>For more information, go to www.nalfon.com or call 1-601-990-9497.</paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.
       
 
  <br/>Issued: 04/2016
      

 </paragraph>
               </text>
               <effectiveTime value="20160429"/>
            </section>
         </component>
         <component>
            <section>
               <id root="57b5ebc3-99d6-4311-9a41-8a55ad0392a2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Nalfon 400mg Capsule</title>
               <text>
                  <renderMultiMedia referencedObject="lbl636297515"/>
               </text>
               <effectiveTime value="20190807"/>
               <component>
                  <observationMedia ID="lbl636297515">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl636297515.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>